Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials

Clinical Ophthalmology

Volumn 10, Issue , 2016, Pages 1103-1110

  Dugel, Pravin U ^a,b   Hillenkamp, Jost ^c   Sivaprasad, Sobha ^d,e   Vögeler, Jessica ^f   Mousseau, Marie Catherine ^g   Wenzel, Andreas ^h   Margaron, Philippe ^h   Hashmonay, Ron ^h   Massin, Pascale ⁱ  

^a RETINAL CONSULTANTS OF ARIZONA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d MOORFIELDS EYE HOSPITAL   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f Novartis Pharma GmbH   (Germany)

^g Novartis Ireland Limited   (Ireland)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Aflibercept; Anti vascular endothelial growth factor; Best corrected visual acuity; Cross trial comparison; Diabetic macular edema; Ranibizumab

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB;

ARTICLE; COMPARATIVE STUDY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

EID: 84975229962     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S100764     Document Type: Article

References (21)

1. American Diabetic Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35(suppl 1):S11-S63.
2. Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27(10):2540-2553.
3. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91(12):1464-1474.
4. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.
5. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064.e-1077.e.
6. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399-2405.
7. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
8. Do DV, Nguyen QD, Boyer D, et al; DA VINCI Study Group. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658-1665.
9. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247-2254.
10. Prunte C, Fajnkuchen F, Mahmood S, et al; The RETAIN Study Group. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. Epub 2015 Oct 9.
11. Mitchell P, Chong V. Baseline predictors of 3-year responses to ranibizumab and laser therapy in patients with visual impairment due to diabetic macular edema - The RESTORE study predictors analysis. ePoster presented at: 13th EURETINA Congress; September 26-29, 2013; Hamburg.
12. Bressler SB, Qin H, Beck RW, et al; Diabetic Retinopathy Clinical Research Network. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012;130(9):1153-1161.
13. Sivaprasad S, Fajnkuchen F, Régnier SA, Wright J, Larsen M. Using patient-level data for meaningful cross-trial comparisons in the visual impairment due to diabetic macular edema treated with anti-VEGF agents. Poster presented at: The Association for Research in Vision and Ophthalmology (ARVO) Meeting; May 3-7, 2015; Denver.
14. Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab. 2013;4(6):151-169.
15. Marzec LN, Maddox TM. Medication adherence in patients with diabetes and dyslipidemia: associated factors and strategies for improvement. Curr Cardiol Rep. 2013;15(11):418.
16. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203.
17. Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940-947.
18. European Medicines Agency [webpage on the Internet]. Lucentis: EPAR-Product Information. EMEA/H/C/000715-IB/0032 [updated November 13, 2015]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf. Accessed February 1, 2016.
19. Finger RP, Wickremasinghe SS, Baird PN, Guymer RH. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Surv Ophthalmol. 2014;59(1):1-18.
20. Tufail A, Xing W, Johnston R, et al. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology. 2014;121(5):1092-1101.
21. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078.e-1086.e.